"Multicenter, open-label, single dose study to evaluate safety, tolerability and pharmacokinetics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared

Administered By

Awarded By

Contributors

Start/End

  • January 1, 2016 - September 30, 2021